计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| E110128-100mg |
100mg |
现货 ![]() |
| |
| E110128-500mg |
500mg |
现货 ![]() |
| |
| E110128-1g |
1g |
现货 ![]() |
| |
| E110128-5g |
5g |
现货 ![]() |
|
| 英文别名 | UNII-0H43101T0J | BCP9000200 | 0H43101T0J | BP-24513 | CAMPTOTHECIN, 7-ETHYL-10-HYDROXY- | SN 38 lactone | AC-1357 | NCGC00167831-05 | Q-200299 | (S)-4,11-Diethyl-4,9-di-OH-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione | GTPL6925 | 1H- |
|---|---|
| 规格或纯度 | Moligand™, ≥98% |
| 英文名称 | 7-Ethyl-10-hydroxycamptothecin |
| 生化机理 | 伊立替康的活性代谢物。拓扑异构酶I的抑制剂。 SN-38治疗的结肠癌细胞系的基因表达分析显示不同的结果:大多数受影响的基因表达下降(最为强烈的为:和受体和激酶活性、信号转导、细胞凋亡、RNA加工、蛋白质代谢相关的基因和转录,参与细胞凋亡,转录,发育和分化的基因的表达上升)。CPT-11(伊立替康)的活性代谢产物。抑制DNA拓扑异构酶I(在P388和Ehrlich细胞中,IC 50值分别为0.74和1.9μM)和DNA和RNA合成(IC 50值分别为77 nM和1.3μM)。 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 备注 | 如果有可能,您尽量在使用的当天配置溶液,并在当天使用完它。但是,如果您需要预先配制储备溶液,我们建议您将溶液等份保存在-20°C的密封小瓶中。通常,它们最多可以使用一个月。在使用前和打开样品瓶之前,我们建议您让您的产品在室温下平衡至少1小时。有毒,请参阅SDS以获取更多信息。需要更多关于溶解度,用法和处理的建议吗?请访问我们的常见问题(FAQ)页面以获取更多详细信息。 |
| 纯度 | ≥98% |
| PubChem SID | 488187375 |
|---|---|
| EC号 | 643-093-9 |
| IIUPAC Name | (19S)-10,19-diethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaene-14,18-dione |
| INCHI | 1S/C22H20N2O5/c1-3-12-13-7-11(25)5-6-17(13)23-19-14(12)9-24-18(19)8-16-15(20(24)26)10-29-21(27)22(16,28)4-2/h5-8,25,28H,3-4,9-10H2,1-2H3/t22-/m0/s1 |
| InChi Key | FJHBVJOVLFPMQE-QFIPXVFZSA-N |
| Smiles | CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)O |
| Isomeric SMILES | CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)O |
| 关联CAS | 86639-52-3 |
| NSC Number | 673596 |
| MeSH Entry Terms | 7 Ethyl 10 hydroxycamptothecin;7-ethyl-10-hydroxycamptothecin;Camptosar;Camptothecin 11;camptothecin-11;CPT 11;CPT-11;CPT11;irinotecan;irinotecan hydrochloride;Irrinotecan;NK012 compound;SN 38;SN 38 11;SN-38;SN-38-11;SN3811 |
| 分子量 | 392.4 |
| Reaxy-Rn | 4279374 |
| Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=4279374&ln= |
| 密度 | 1.6 |
|---|---|
| 敏感性 | 对热敏感 |
| 比旋光度 | +20.0 to +30.0 deg(C=0.2, THF) |
| 熔点 | 217°C |
| 分子量 | 392.400 g/mol |
| XLogP3 | 1.400 |
| 氢键供体数Hydrogen Bond Donor Count | 2 |
| 氢键受体数Hydrogen Bond Acceptor Count | 6 |
| 可旋转键计数Rotatable Bond Count | 2 |
| 精确质量Exact Mass | 392.137 Da |
| 单同位素质量Monoisotopic Mass | 392.137 Da |
| 拓扑极表面积Topological Polar Surface Area | 100.000 Ų |
| 重原子数Heavy Atom Count | 29 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 820.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 1 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
| 批号(Lot Number) | 证书类型 | 货号 |
|---|---|---|
| 分析证书 | E110128 | |
| 分析证书 | E110128 | |
| 分析证书 | E110128 | |
| 分析证书 | E110128 | |
| 分析证书 | E110128 | |
| 分析证书 | E110128 | |
| 分析证书 | E110128 | |
| 分析证书 | E110128 | |
| 分析证书 | E110128 | |
| 分析证书 | E110128 | |
| 分析证书 | E110128 | |
| 分析证书 | E110128 | |
| 分析证书 | E110128 | |
| 分析证书 | E110128 | |
| 分析证书 | E110128 |
| 1. Peter S et al.. (2016) Cell-based high-throughput compound screening reveals functional interaction between oncofetal HMGA2 and topoisomerase I.. Nucleic Acids Res, [PMID:27587582] |
| 2. Winkler C et al.. (2021) SLFN11 informs on standard of care and novel treatments in a wide range of cancer models.. Br J Cancer, 124 (5): (951-962). [PMID:33339894] |
| 3. Lili Cheng, Peng Zhang, Yadong Liu, Zhuoyin Liu, Junjie Tang, Langtao Xu, Jie Liu. (2023) Multifunctional hybrid exosomes enhanced cancer chemo-immunotherapy by activating the STING pathway. BIOMATERIALS, 301 (122259). [PMID:37531777] [10.1016/j.biomaterials.2023.122259] |
| 4. Linjie Yang, Jingyi Hong, Jing Di, Yifei Guo, Meihua Han, Meifeng Liu, Xiangtao Wang. (2023) 10-Hydroxycamptothecin (HCPT) nanosuspensions stabilized by mPEG1000-HCPT conjugate: high stabilizing efficiency and improved antitumor efficacy. International Journal of Nanomedicine, [PMID:28553107] [10.2147/IJN.S134005] |
| 5. Jinjin Chen, Lulu Zhou, Chunhui Wang, Yunhao Sun, Yonglin Lu, Ruihao Li, Xiaochun Hu, Mengyao Chen, Lv Chen, Keke Chai, Tianming Yao, Shuo Shi, Chunyan Dong. (2020) A multifunctional SN38-conjugated nanosystem for defeating myelosuppression and diarrhea induced by irinotecan in esophageal cancer. Nanoscale, 12 (41): (21234-21247). [PMID:33063070] [10.1039/D0NR06266A] |
| 6. Hua Sun, Xiaotong Zhou, Baojian Wu. (2015) Accurate identification of UDP-glucuronosyltransferase 1A1 (UGT1A1) inhibitors using UGT1A1-overexpressing HeLa cells. XENOBIOTICA, 45 (11): (945-953). [PMID:26068529] [10.3109/00498254.2015.1033502] |
| 7. Zede Wu, Qiuyu Li, Kai Zhu, Shuting Zheng, Honglei Hu, Meirong Hou, Li Qi, Siwen Chen, Yikai Xu, Bingxia Zhao, Chenggong Yan. (2024) Cancer Radiosensitization Nanoagent to Activate cGAS-STING Pathway for Molecular Imaging Guided Synergistic Radio/Chemo/Immunotherapy. Advanced Healthcare Materials, (2303626). [PMID:38387885] [10.1002/adhm.202303626] |
| 8. Feng Gao, Jun Guo, Shihao Liu, Feng Zhang, Yi Zhang, Liping Wang. (2024) Empowering hydrophobic anticancer drugs by ultrashort peptides: General Co-assembly strategy for improved solubility, targeted efficacy, and clinical application. JOURNAL OF COLLOID AND INTERFACE SCIENCE, 667 (119). [PMID:38631250] [10.1016/j.jcis.2024.04.013] |
| 9. Xiaojiang Zhang, Yujie Zhang, Pengqian Wang, Feiyu Shi, Siyuan Du, Zhe Zhang, Daocheng Wu, Junjun She, Ya Wang. (2025) Infinite Coordination Polymer Polydopamine Nanocomposites Dual-Pathway Multistep Induction of Long-Term Hyperimmunity Combined With Photothermal-Chemo Synergistic Therapy Colorectal Cancer. Aggregate, (e730). [10.1002/agt2.730] |
| 10. Ming Li, Xinrui Zhang, Yujie Zhou, Yuteng Chu, Jie Shen, Yue Cai, Xuanrong Sun. (2024) Near Infrared-Activatable Biomimetic Nanoplatform for Tumor-Specific Drug Release, Penetration and Chemo-Photothermal Synergistic Therapy of Orthotopic Glioblastoma. International Journal of Nanomedicine, [PMID:39011386] [10.2147/IJN.S466268] |